InsiderTrades

Form 4 for LGND LIGAND PHARMACEUTICALS INC

Accepted 2021-11-12 00:00:00 ET · period of report 2021-11-11 · accession 0000886163-21-000132 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2021-11-12 2021-11-11 LGND FOEHR MATTHEW W Pres, COO M - OptEx $28.54 +12.2K 177.7K +7% +$347.8K
D 2021-11-12 2021-11-11 LGND FOEHR MATTHEW W Pres, COO S - Sale+OE $163.02 -11.2K 166.5K -6% -$1.82M
DM 2021-11-12 2021-11-11 LGND FOEHR MATTHEW W Pres, COO M - OptEx $0.00 -12.2K 24.3K -33% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-11-11 M A 1,028 $100.38 166,525 D — —
2 Common Common Stock 2021-11-11 M A 11,160 $21.92 177,685 D — —
3 Common Common Stock 2021-11-11 S D 11,160 $163.02 166,525 D — — (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.41 to $166.38, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4 Derivative Employee Stock Option (right to buy) 2021-11-11 M D 11,160 $0.00 0 D $21.92 · — to 2023-02-15 11,160 Common Stock (F2) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.
5 Derivative Employee Stock Option (right to buy) 2021-11-11 M D 1,028 $0.00 24,348 D $100.38 · — to 2027-02-24 1,028 Common Stock (F3) Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/24/2017.